Across TCGA pan-cancer cohorts, HACD2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HACD2 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher HACD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HACD2 expression acts as an unfavorable survival marker.

ESCA and STAD are the cancer types where HACD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: HACD2 tumor-vs-normal RNA expression · all HACD2 data types